Welcome to our dedicated page for Fulgent Genetics SEC filings (Ticker: FLGT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Fulgent Genetics, Inc. (NASDAQ: FLGT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Fulgent is a technology-based company with a laboratory services business and a therapeutic development business, and its SEC reports offer detailed information on both areas. Investors can review annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K to understand how the company presents its financial condition, results of operations, and material events.
Fulgent’s earnings-related 8-K filings reference press releases that discuss revenue, core revenue, GAAP and non-GAAP income or loss, gross profit and margin, and adjusted EBITDA. These filings also describe how the company defines and reconciles non-GAAP measures to the most directly comparable GAAP metrics, and how management uses these measures to evaluate performance. For those analyzing FLGT stock, these documents are a primary source for understanding trends in the laboratory services and therapeutic development segments, as well as the company’s cash position and stock repurchase activity.
In addition to financial results, Fulgent uses Form 8-K to report other significant developments, such as preliminary clinical data from its oncology programs. For example, the company has filed an 8-K to furnish a press release describing preliminary data from a phase 2 trial of FID-007 in combination with cetuximab in recurrent or metastatic head and neck squamous cell carcinoma. Such filings provide context on the progress and risk profile of its therapeutic development pipeline.
On this page, users can track FLGT filings in near real time as they are made available through EDGAR. Stock Titan’s tools surface key forms such as 10-K for annual overviews, 10-Q for quarterly updates, and 8-K for material events, with AI-powered summaries that help explain complex sections and highlight important points. For those interested in governance, compensation, or potential insider activity, related SEC documents and forms can also be reviewed alongside the company’s broader disclosure record.
Fulgent Genetics files its annual report describing a dual business in diagnostic laboratory services and cancer therapeutics. The company combines broad pathology and genetic testing with a nanoencapsulation drug platform, including FID-007 in Phase 2 for head and neck cancer and FID-022 in an early Phase 1/1b trial.
One aggregated customer represented 22% of revenue in both 2025 and 2024, highlighting customer concentration risk. The report outlines extensive U.S. and international regulatory oversight of its labs and drug development, plus evolving rules for lab-developed tests and European IVDR compliance.
The filing notes an aggregate market value of non‑affiliate equity of about $284.3 million as of June 30, 2025, and 31,230,632 common shares outstanding as of February 23, 2026.
Fulgent Genetics reported fourth-quarter 2025 revenue of $83.3 million, up 9% year over year, and a GAAP net loss of $23.4 million or ($0.76) per share. Non-GAAP income for the quarter was $5.2 million, or $0.16 per diluted share.
For full year 2025, revenue reached $322.7 million, growing 14% year over year. The company posted a GAAP net loss of $60.5 million, or ($1.97) per share, but generated full-year non-GAAP income of $13.2 million, or $0.42 per diluted share.
Fulgent ended 2025 with $705.5 million in cash, cash equivalents, restricted cash, and investments in marketable securities, excluding an anticipated tax refund of about $106.3 million. For 2026, it guides to revenue of roughly $350 million, a non-GAAP loss of about ($1.45) per share, and year-end cash and investments of about $685 million, assuming receipt of tax refunds and closing of the Bako and StrataDx acquisition.
Fulgent Genetics CFO Paul Kim reported equity awards and related tax withholdings in company stock. On February 23–24, 2026, he acquired multiple common stock grants tied to time-based and performance-based restricted stock units that vested upon meeting performance milestones from awards granted in 2023, 2024, and 2025.
To satisfy tax withholding obligations triggered by these vestings, shares were withheld at prices around $23 per share rather than sold on the open market. A new restricted stock unit grant will vest over three years, with one-third vesting 12 months after March 1, 2026 and the remainder in quarterly installments, subject to continued service.
Fulgent Genetics, Inc. President and COO Jian Xie reported a mix of stock awards and tax-related share withholdings. On February 24, 2026, he acquired several blocks of common stock at no cost through vested performance-based restricted stock units granted in 2023, 2024, and 2025.
He also received a new grant of 31,962 restricted stock units that vest over three years starting 12 months after March 1, 2026. Shares totaling 3,163, 8,254, 14,751 and 655 were withheld at prices around $23 per share to satisfy tax obligations. Additional indirect holdings are reported in The Hsieh Family Dynasty Trust, where Xie notes only a pecuniary interest.
Fulgent Genetics Chief Scientific Officer Hanlin Gao reported equity awards and related tax withholdings in company stock. On February 24, 2026, he acquired 4,891, 12,762, 22,806 and 26,661 shares of common stock at $0 per share through grants and vesting of restricted stock units, including performance-based awards tied to milestones from grants made in 2023, 2024 and 2025.
To cover tax obligations from these vestings, 2,489, 4,661, 8,149 and 403 shares were withheld at prices of about $23.09 and $23.01 per share. After these transactions, Gao directly owned 976,316 to 1,002,977 shares across the reported line items, reflecting routine compensation-related activity rather than open-market buying or selling.
Fulgent Genetics, Inc. director and CEO Ming Hsieh reported multiple equity-related transactions in the company’s common stock. On February 24, 2026, he acquired shares at a price of $0.00 per share through grants and vesting of restricted stock units tied to performance milestones and service-based conditions.
On the same date, shares were also disposed of at $23.09 per share, and on February 23, 2026 at $23.01 per share, to satisfy tax withholding obligations triggered by those vestings, rather than open‑market sales. The filing also shows significant indirect holdings through the Dynasty Trust, The Ming Hsieh Trust, a Uniform Transfers to Minors Act account, and an immediate family member’s account, with varying levels of voting and dispositive power as described in the footnotes.
Fulgent Genetics, Inc. received an amended Schedule 13G/A (Amendment No. 4) reporting institutional ownership of its common stock. Investment entities including Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of about 3.0% of the common stock, including 939,375 shares with shared voting and dispositive power for several reporting persons and 918,503 shares for Integrated Core Strategies. The filers certify the shares were not acquired to change or influence control of Fulgent Genetics.
Fulgent Genetics Chief Scientific Officer Hanlin Gao reported a tax-related share withholding. On January 26, 2026, 1,331 shares of common stock were withheld at $27.53 per share to cover taxes from vested restricted stock units. After this, Gao directly owned 951,559 shares of Fulgent Genetics common stock.
Fulgent Genetics, Inc. President and COO Jian Xie reported a tax-related share withholding on common stock. On January 26, 2026, 4,711 shares of Fulgent Genetics common stock were withheld at $27.53 per share to cover tax obligations from the vesting of restricted stock units tied to a prior merger agreement.
After this transaction, Xie directly beneficially owns 332,038 common shares. In addition, 220,816 common shares are reported as indirectly owned through The Hsieh Family Dynasty Trust, where Xie serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics CFO Paul Kim reported a routine tax-related share withholding. On January 26, 2026, 3,004 shares of Fulgent Genetics common stock were withheld at $27.53 per share to cover tax obligations arising from the vesting of previously granted restricted stock units.
After this withholding, Kim beneficially owned 328,146 shares of common stock in direct form. The transaction was coded "F," indicating a tax withholding event linked to equity compensation rather than an open-market sale.